Command Palette

Search for a command to run...

Clinical Trials · NCT03029351

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

TerminatedPhase 4Exenatide (Prohibited)
Phase
Phase 4
Recruitment status
Terminated
Sponsor
University at Buffalo
Enrollment
15
Start date
Jan 2017
Locations
1 site, United States
Primary endpoint
Change From Baseline in Urinary Albuminuria Levels
View Exenatide compound reference